AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
etripamil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| calcium channel blockers, verapamil derivatives | 5792 | 1593673-23-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Etripamil is an L-type calcium influx inhibitor (slow channel blocker or calcium ion antagonist). Etripamil exerts its pharmacologic effect by modulating the influx of ionic calcium across the cell membrane of the AV nodal cells as well as arterial smooth muscles and contractile myocardial cells. By interrupting reentry at the AV node, etripamil can restore sinus rhythm in patients with PSVT.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 12, 2025 | FDA | Milestone Pharmaceuticals |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C08DA03 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS Phenylalkylamine derivatives |
| MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
| MeSH PA | D002121 | Calcium Channel Blockers |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D049990 | Membrane Transport Modulators |
Related Drugs by ATC class:
C08DA Phenylalkylamine derivatives 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Paroxysmal supraventricular tachycardia | indication | 67198005 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 70MG | CARDAMYST | MILESTONE PHARMS USA | N218571 | Dec. 12, 2025 | RX | SPRAY | NASAL | 10010522 | June 19, 2028 | TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA |
| 70MG | CARDAMYST | MILESTONE PHARMS USA | N218571 | Dec. 12, 2025 | RX | SPRAY | NASAL | 9463179 | June 19, 2028 | TREATMENT OF A CARDIAC ARRHYTHMIA |
| 70MG | CARDAMYST | MILESTONE PHARMS USA | N218571 | Dec. 12, 2025 | RX | SPRAY | NASAL | 10117848 | April 13, 2036 | TREATMENT OF A CARDIAC ARRHYTHMIA |
| 70MG | CARDAMYST | MILESTONE PHARMS USA | N218571 | Dec. 12, 2025 | RX | SPRAY | NASAL | 12257224 | July 15, 2042 | TREATMENT OF A CARDIAC ARRHYTHMIA |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 70MG | CARDAMYST | MILESTONE PHARMS USA | N218571 | Dec. 12, 2025 | RX | SPRAY | NASAL | Dec. 12, 2030 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | BLOCKER | IC50 | 7.64 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| 1593673-23-4 | SECONDARY_CAS_RN |
| CHEMBL3707312 | ChEMBL_ID |
| C000656646 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB12605 | DRUGBANK_ID |
| 4044475 | VANDF |
| C4519151 | UMLSCUI |
| 10134 | INN_ID |
| D10932 | KEGG_DRUG |
| 91824132 | PUBCHEM_CID |
| 399954 | MMSL |
| 44585 | MMSL |
| d10348 | MMSL |
| 020310 | NDDF |
| 14304 | IUPHAR_LIGAND_ID |
| S82A18Y42P | UNII |
| 2730302 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cardamyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 83468-070 | SPRAY | 70 mg | NASAL | NDA | 28 sections |